Detail
| LncRNA Name | EPIC1 |
| Synonyms | NA |
| Region | NA Sequence |
| Ensembl | NA |
| RefSeq | NA |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✔ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Western blot, in vitro knockdown, RIP etc. |
| Sample | cell lines (MCF10A,BT-20,BT-474,HCC1937,Hs578T,MDA-MB-231,MDA-MB-361,MDA-MB-468,MCF-7,T-47D,ZR-75-1,A2780,A2780cis,IGR-OV-1NIH:OVCAR-3,OVCAR-4,OVCAR-8,SK-OV-3), breast cancer tissues |
| Expression Pattern | up-regulated |
| Function Description | Overexpression of EPIC1 is associated with poor prognosis in luminal B breast cancer patients and enhances tumor growth in vitro and in vivo. Mechanistically, EPIC1 promotes cell-cycle progression by interacting with MYC through EPIC1's 129-283 nt region. EPIC1 knockdown reduces the occupancy of MYC to its target genes (e.g., CDKN1A, CCNA2, CDC20, and CDC45). MYC depletion abolishes EPIC1's regulation of MYC target and luminal breast cancer tumorigenesis in vitro and in vivo. |
| Pubmed ID | 29622465 |
| Year | 2018 |
| Title | lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. |
| External Links |
| Links for EPIC1 | GenBank HGNC lncrnadb Noncode |
| Links for breast cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.